initi
screen
compound
perform
briefli
cell
constitut
express
gaussia
luciferas
transfect
firefli
report
seed
plate
media
contain
serial
dilut
compound
ad
cell
hour
hour
supernat
contain
collect
cell
viabil
assess
cell
lyze
measur
firefli
luciferas
activ
indic
hcv
rna
replic
supernat
cell
use
infect
target
cell
lyze
hour
report
level
measur
whole
life
cycl
assess
assay
perform
cell
cellsml
seed
well
plate
day
experi
follow
day
cell
treat
concanamycin
nm
hour
infect
concentr
report
virus
presenc
concanamycin
cell
wash
twice
salin
incub
medium
contain
concanamycin
hour
subsequ
cell
incub
minut
ph
ph
citric
acid
buffer
mcilvain
buffer
system
fresh
medium
ad
cell
continu
presenc
concanamycin
hour
longer
medium
chang
infect
measur
assess
report
activ
hour
cell
seed
plate
cellswel
day
infect
viru
stock
hour
presenc
two
concentr
flunarizin
dimethylsulfoxid
dmso
addit
fresh
medium
hour
hour
later
cell
split
flunarizin
dmso
ad
hour
hour
supernat
use
infect
new
cell
accord
procedur
perform
first
infect
cycl
infect
naiv
cell
split
cell
approxim
week
cell
allow
produc
virus
absenc
compound
hour
supernat
harvest
core
measur
immunosorb
assay
stock
dmso
flunarizin
flunarizin
passag
virus
normal
core
level
use
infect
cell
seed
coverslip
plate
infect
effici
assess
immunofluoresc
use
monoclon
antibodi
dilut
bound
primari
antibodi
detect
use
goat
antimous
immunoglobulin
secondari
antibodi
conjug
alexa
fluor
sigma
dilut
nuclear
dna
stain
use
dilut
licens
hcv
drug
target
either
polyprotein
process
proteas
inhibitor
rna
replic
inhibitor
polymeras
inhibitor
identifi
molecul
would
complement
therapi
may
reveal
novel
insight
life
cycl
step
aim
identifi
inhibitor
novel
mode
action
addit
molecul
suffer
potenti
viral
establish
drug
class
thu
chose
whole
life
cycl
screen
assay
base
chimer
report
viru
interrog
hcv
entri
rna
translat
polyprotein
process
rna
replic
viru
assembl
http
inhibitor
influenza
viru
ion
channel
use
treat
human
hcv
ion
channel
protein
essenti
viru
product
screen
librari
compound
includ
sever
clinic
approv
ion
channel
inhibitor
use
treat
heart
neurolog
condit
http
fifteen
compound
inhibit
hcv
entri
assembl
releas
http
flunarizin
display
median
inhibitori
concentr
valu
nm
http
median
cytotox
concentr
valu
equival
therapeut
index
median
cytotox
fig
flunarizin
recent
emerg
inhibitor
independ
screen
howev
mode
action
remain
unclear
moreov
explor
molecul
antivir
primari
human
hepatocyt
vivo
address
limit
inocul
cell
viru
presenc
compound
subsequ
wash
away
unbound
viru
compound
activ
decreas
dose
wherea
express
affect
therebi
indic
absenc
cytotox
fig
contrast
addit
flunarizin
hcv
cell
reduc
releas
infecti
viru
particl
determin
immunosorb
assay
limit
dilut
assay
median
tissu
cultur
infect
dose
http
interestingli
inhibit
entri
hcv
pseudoparticl
hcvpp
carri
glycoprotein
http
thu
flunarizin
select
inhibit
entri
authent
cell
hcv
hcvcc
hcvpp
moreov
inhibit
rna
replic
viru
assembl
fig
http
next
infect
primari
human
hepatocyt
particl
presenc
telaprevir
flunarizin
dmso
solvent
flunarizin
significantli
inhibit
de
novo
product
infecti
viru
hour
hour
inocul
compar
inocul
presenc
solvent
fig
final
administ
flunarizin
hcv
cell
entri
report
mice
express
crucial
human
cofactor
hcv
entri
carri
luciferas
report
gene
activ
cre
anim
challeng
infecti
express
cre
recombinas
flunarizin
serum
level
reach
averag
nm
close
vitro
median
effect
concentr
valu
describ
importantli
dose
activ
luciferas
express
significantli
repress
fig
thu
flunarizin
inhibit
hcv
cell
entri
human
primari
liver
cell
vitro
human
mous
hepatocyt
vivo
flunarizin
inhibit
infect
vesicular
stomat
viru
human
coronaviru
http
investig
prevent
hcv
entri
across
seven
hcv
genotyp
therefor
cell
inocul
chimer
hcv
virus
presenc
increas
dose
flunarizin
fig
strain
display
resist
toward
drug
valu
order
magnitud
greater
isol
show
intermedi
phenotyp
valu
isol
highli
suscept
display
valu
respect
map
determin
flunarizin
suscept
shuffl
viral
core
protein
resist
suscept
transfer
render
result
viru
resist
flunarizin
fig
contrast
insert
protein
confer
flunarizin
resist
convers
replac
sequenc
render
chimera
suscept
drug
fig
therefor
suscept
flunarizin
govern
determin
resid
gene
likewis
exchang
structur
protein
virus
carri
gene
display
greater
suscept
flunarizin
compar
harbor
glycoprotein
http
chimer
viru
carri
backbon
produc
infecti
viru
exhibit
partial
resist
flunarizin
indic
determin
influenc
suscept
drug
http
next
use
hcv
particl
primari
gene
sequenc
also
clinic
isol
suscept
flunarizin
wherea
isol
resist
fig
final
creat
hcv
particl
carri
protein
six
addit
subtyp
includ
e
k
q
r
strain
suscept
inhibit
flunarizin
albeit
variabl
degre
fig
collect
indic
flunarizin
interfer
hcv
entri
target
viral
protein
function
almost
subtyp
test
clear
prefer
viral
genotyp
corrobor
target
flunarizin
passag
hcv
presenc
flunarizin
week
observ
drug
resist
infect
cell
viru
popul
cultur
presenc
drug
poorli
inhibit
flunarizin
compar
virus
cultur
presenc
dmso
fig
sequenc
reveal
conserv
amino
acid
mutat
posit
genom
genom
genom
genom
engin
parent
viru
either
alon
combin
insert
mutat
chang
suscept
flunarizin
fig
contrast
mutat
mutat
increas
viru
resist
combin
three
envelop
protein
mutat
confer
maxim
resist
chang
interestingli
residu
fulli
conserv
among
hcv
sequenc
deposit
gene
bank
databas
fig
addit
isol
carri
correl
suscept
flunarizin
viru
wherea
sequenc
encod
glycin
posit
http
final
mutat
resid
hypervari
region
import
yet
viral
neutral
epitop
full
conserv
high
level
conserv
may
indic
import
function
constraint
could
limit
viral
escap
vivo
explor
evalu
neutral
viru
potent
monoclon
antibodi
neutral
antibodi
significantli
enhanc
flunarizin
resist
mutat
fig
collect
combin
three
part
affect
highli
conserv
necessari
confer
resist
flunarizin
mutat
render
hcv
suscept
neutral
antibodi
suggest
high
barrier
viral
resist
precis
defin
mode
action
flunarizin
conduct
experi
includ
hcv
entri
inhibitor
arrest
hcv
infect
distinct
stage
cell
entri
http
flunarizin
resist
reach
time
point
similar
resist
inhibitor
endosom
acidif
eg
concanamycin
suggest
flunarizin
inhibit
late
entri
step
explor
use
hcv
plasma
membran
fusion
assay
cell
pretreat
concanamycin
prevent
viral
entri
membran
fusion
normal
rout
acidifi
endosom
fig
circumst
hcv
fusion
thu
product
infect
trigger
briefli
expos
viru
inocul
cell
low
ph
buffer
hcv
membran
fusion
requir
receptor
interact
includ
bind
viru
recept
exogen
trigger
low
ph
buffer
incub
approxim
hour
thu
cell
continu
treat
concanamycin
addit
drug
ad
either
directli
viru
inocul
throughout
experi
hour
shift
fig
protocol
incub
low
ph
buffer
protocol
ii
directli
subsequ
fusion
trigger
low
ph
wash
protocol
iii
buffer
neutral
ph
use
control
product
infect
fulli
depend
low
fusion
expect
hcv
infect
occur
cell
expos
low
ph
buffer
luciferas
express
background
uninfect
cell
detect
fig
dmso
ad
cell
accord
protocol
ii
iii
low
ph
wash
result
high
luciferas
activ
approxim
background
mock
infect
cell
viru
inocul
cell
treat
neutral
ph
buffer
fig
addit
bafilomycin
like
concanamycin
prevent
acidif
endosom
antivir
effect
regardless
administr
protocol
confirm
hcv
access
cell
exogen
administr
low
ph
independ
endosom
acidif
moreov
inhibitor
complet
lost
antivir
activ
appli
directli
low
ph
fusion
trigger
indic
exert
antivir
activ
block
hcv
entri
upstream
membran
fusion
fig
protocol
iii
flunarizin
reduc
hcv
infect
essenti
background
level
administ
directli
viru
inocul
thu
present
viru
traffick
cell
surfac
hour
low
ph
fusion
treatment
howev
flunarizin
fulli
antivir
ad
select
low
ph
wash
step
fig
protocol
ii
interestingli
virus
carri
two
resist
mutat
longer
inhibit
fig
wherea
mutat
alon
suffici
confer
flunarizin
resist
fusion
assay
result
indic
flunarizin
specif
target
hcv
membran
fusion
resist
primarili
mediat
two
mutat
within
corrobor
flunarizin
target
hcv
fusion
use
imag
assay
fluoresc
dii
hcv
entri
polar
hepatocyt
cultur
baktash
et
al
unpublish
data
enabl
quantif
hcv
singl
particl
cell
surfac
traffick
tight
junction
complex
viru
intern
earli
endosom
ultim
fusion
uncoat
follow
fusion
uncoat
increas
distribut
fluoresc
due
mix
cellular
membran
cell
grown
extracellular
matrix
form
hepat
spheroid
treat
either
flunarizin
vehicl
control
infect
imag
coloc
either
tight
junction
marker
zona
earli
endosom
marker
earli
endosom
time
cours
entri
observ
flunarizin
affect
local
tight
junction
fig
b
affect
intern
local
earli
endosom
fig
treatment
flunarizin
decreas
fusion
evidenc
significantli
lower
fluoresc
volum
minut
shift
compar
vehicl
control
fig
f
therefor
flunarizin
affect
hcv
traffick
endocytosi
inhibit
fusion
hcv
endosom
membran
flunarizin
channel
inhibitor
belong
group
diarylmethyl
piperazin
drug
rang
structur
relat
drug
eg
pimozid
known
also
block
ion
channel
use
antipsychot
moreov
phenothiazin
fluphenazin
trifluoperazin
also
import
drug
phenothiazin
group
resembl
biarylmethyl
group
inde
emerg
potent
hcv
inhibitor
screen
http
therefor
explor
inhibit
ion
channel
gener
essenti
antivir
activ
molecul
furthermor
investig
drug
inhibit
hcv
antivir
mechan
compar
flunarizin
address
explor
influenc
n
acid
ethylen
glycol
tetraacet
acid
two
agent
sequest
intracellular
extracellular
pool
respect
antivir
activ
flunarizin
although
n
acid
ethylen
glycol
tetraacet
acid
administ
high
dose
modul
antivir
activ
flunarizin
indic
inhibit
hcv
entri
flunarizin
depend
avail
fig
next
explor
three
inhibitor
channel
interfer
hcv
infect
none
molecul
inhibit
infect
parent
hcv
hcv
fig
contrast
phenothiazin
fluphenazin
trifluoperazin
pimozid
preferenti
inhibit
parent
viru
less
activ
variant
flunarizin
resist
mutat
antivir
activ
two
molecul
inhibit
hcv
cell
entri
differ
molecular
mechan
influenc
mutat
fig
work
prepar
et
al
report
select
phenothiazin
inhibit
hcv
entri
potenti
increas
fluiditi
prompt
us
explor
viral
suscept
flunarizin
correl
suscept
modul
membran
fluiditi
achiev
deplet
cholesterol
use
interestingli
observ
significantli
suscept
cholesterol
deplet
viru
high
endogen
flunarizin
resist
fig
moreov
also
variant
significantli
resist
deplet
cholesterol
compar
parent
fig
suggest
differ
depend
hcv
fusion
machineri
membran
properti
may
part
determin
suscept
flunarizin
phenothiazin
pimozid
howev
experi
drug
modul
membran
fluiditi
http
cellular
cholesterol
content
http
suggest
membran
chang
respons
fusion
inhibit
notabl
pimozid
antivir
vivo
fig
individu
mutat
confer
partial
resist
pimozid
like
flunarizin
http
final
fluphenazin
trifluoperazin
pimozid
display
prefer
gt
similar
flunarizin
howev
pimozid
fluphenazin
display
much
improv
coverag
valu
case
pimozid
fluphenazin
fig
conclus
antivir
activ
flunarizin
relat
compound
directli
link
abil
inhibit
ion
channel
nevertheless
viral
compar
genotyp
specif
flunarizin
phenothiazin
pimozid
strongli
argu
share
antivir
mode
action
screen
librari
clinic
licens
drug
identifi
four
relat
ion
channel
inhibitor
prevent
hcv
entri
vitro
vivo
provid
evid
base
chimer
virus
resist
mutat
molecul
select
target
hcv
function
entri
moreov
experi
singl
particl
track
indic
drug
specif
inhibit
hcv
membran
fusion
final
domain
carri
resist
mutat
like
play
key
role
membran
fusion
sever
scenario
molecul
prevent
hcv
membran
fusion
possibl
firstli
drug
inhibit
cellular
channel
may
prevent
fusion
chang
flux
hcv
target
cell
andor
directli
block
interact
hcv
channel
critic
membran
fusion
howev
test
channel
target
drug
also
arrest
hcv
infect
moreov
sequestr
modul
antivir
activ
flunarizin
therefor
consid
unlik
inhibit
channel
drug
would
use
hcv
fashion
respons
activ
class
molecul
secondli
possibl
flunarizin
pimozid
phenothiazin
directli
bind
therebi
inhibit
membran
fusion
genotyp
specif
antivir
activ
support
notion
sequenc
variat
may
prevent
drug
bind
howev
hcvpp
carri
viral
envelop
protein
hcvcc
particl
inhibit
flunarizin
argu
also
chockalingam
et
hu
et
report
resist
hcvpp
flunarizin
lead
conclud
flunarizin
like
entri
inhibitor
data
howev
show
flunarizin
inhibit
entri
authent
hcv
stage
membran
fusion
highlight
yet
unexplor
differ
mode
hcvpp
hcvcc
membran
fusion
may
aris
hcvpp
produc
cell
rather
human
liver
cell
consequ
hcvpp
could
differ
lipid
lipoprotein
composit
thu
affect
cell
entri
notabl
report
receptor
usag
differ
hcvcc
hcvpp
former
use
cholesterol
absorpt
receptor
cell
furthermor
meerten
colleagu
observ
cholesterol
deplet
host
cell
effect
entri
hcvpp
wherea
antivir
therefor
resist
mutat
identifi
us
could
part
direct
drug
bind
site
could
modul
conform
function
membran
fusion
seem
exquisit
hcvcc
particl
domain
residu
previous
implic
harbor
hcv
fusion
peptid
base
phylogenet
comparison
relat
flavivirus
sequenc
conserv
observ
drug
specif
inhibit
membran
fusion
select
viral
resist
region
indirectli
support
notion
peptid
critic
fusion
crystal
structur
reveal
evid
major
role
fusion
protein
assum
primari
fusion
protein
support
earlier
final
possibl
lipophil
drug
perturb
membran
properti
critic
viru
membran
fusion
fact
work
prepar
et
al
report
case
specif
phenothiazin
includ
fluphenazin
trifluoperazin
also
character
intriguingli
observ
correl
hcv
suscept
flunarizin
suscept
hcv
cholesterol
chang
membran
properti
result
compat
notion
flunarizin
pimozid
like
phenothiazin
modul
membran
fluiditi
antivir
principl
group
compound
turn
antivir
activ
molecul
impli
viral
strain
differ
regard
membran
requir
fusion
cholesterol
deplet
experi
report
show
suscept
cholesterol
deplet
compar
strain
support
notion
howev
unlik
et
al
consist
thoma
verkleij
observ
modif
membran
fluiditi
flunarizin
relat
discrep
studi
may
due
differ
assay
setup
includ
composit
liposom
http
moreov
flunarizin
relat
compound
extract
cholesterol
cell
even
upon
prolong
incub
http
flunarizin
also
affect
biophys
membran
properti
exampl
inhibit
format
hexagon
hii
homolog
format
neg
curvatur
requir
fusion
viral
cellular
notabl
cholesterol
deplet
also
affect
abil
lipid
bilay
form
neg
curvatur
requir
fusion
flunarizin
may
therefor
inhibit
hcv
infect
affect
biophys
properti
cellular
membran
also
depend
cholesterol
content
fluiditi
combin
three
amino
acid
chang
necessari
obtain
viral
resist
flunarizin
moreov
resist
mutat
affect
part
complet
highli
conserv
residu
significantli
increas
viru
neutral
two
antibodi
suggest
barrier
viral
resist
could
rel
high
vivo
therefor
flunarizin
relat
compound
merit
consider
repurpos
potenti
adjunct
therapi
patient
due
broader
gt
coverag
case
pimozid
trifluoperazin
fluphenazin
also
difficult
treat
author
name
bold
design
share
authorship
